blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3645012

EP3645012 - MODIFIED UBE3A GENE FOR A GENE THERAPY APPROACH FOR ANGELMAN SYNDROME [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  31.05.2024
Database last updated on 16.09.2024
FormerRequest for examination was made
Status updated on  03.04.2020
FormerThe international publication has been made
Status updated on  04.01.2019
Most recent event   Tooltip06.08.2024New entry: Additional fee for renewal fee: despatch of communication + time limit 
Applicant(s)For all designated states
University Of South Florida
3802 Spectrum Blvd., Suite 100
Tampa, FL 33612 / US
[2020/19]
Inventor(s)01 / NASH, Kevin Ron
6215 Soaring Avenue
Temple Terrace Florida 33617 / US
02 / WEEBER, Edwin John
5407 Conch Shell Place
Apollo Beach Florida 33572 / US
 [2020/19]
Representative(s)Cabinet Chaillot
16/20, avenue de l'Agent Sarre
B.P. 74
92703 Colombes Cedex / FR
[2020/19]
Application number, filing date18823174.028.06.2018
[2020/19]
WO2018US39980
Priority number, dateUS201762525787P28.06.2017         Original published format: US 201762525787 P
[2020/19]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019006107
Date:03.01.2019
Language:EN
[2019/01]
Type: A1 Application with search report 
No.:EP3645012
Date:06.05.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 03.01.2019 takes the place of the publication of the European patent application.
[2020/19]
Search report(s)International search report - published on:US03.01.2019
(Supplementary) European search report - dispatched on:EP01.06.2021
ClassificationIPC:A61K31/711, C12N15/85, C12P19/34
[2020/19]
CPC:
C12N9/93 (EP); A61K35/761 (US); A61K31/711 (EP);
A61K48/005 (EP); A61K48/0058 (US); A61K48/0066 (US);
A61P25/28 (US); C07K14/62 (US); C12N15/86 (EP,US);
C12Y603/02019 (EP); C12N2750/14143 (EP); C12N2810/40 (US);
C12N2810/854 (US); C12N2840/007 (US) (-)
C-Set:
A61K31/711, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/19]
TitleGerman:MODIFIZIERTES UBE3A-GEN FÜR EINEN GENTHERAPIEANSATZ FÜR EIN ANGELMAN-SYNDROM[2020/19]
English:MODIFIED UBE3A GENE FOR A GENE THERAPY APPROACH FOR ANGELMAN SYNDROME[2020/19]
French:GÈNE UBE3A MODIFIÉ POUR UNE APPROCHE DE THÉRAPIE GÉNIQUE DU SYNDROME D'ANGELMAN[2020/19]
Entry into regional phase28.01.2020National basic fee paid 
28.01.2020Search fee paid 
28.01.2020Designation fee(s) paid 
28.01.2020Examination fee paid 
Examination procedure28.01.2020Examination requested  [2020/19]
29.12.2021Amendment by applicant (claims and/or description)
03.06.2024Despatch of a communication from the examining division (Time limit: M04)
Fees paidRenewal fee
25.06.2020Renewal fee patent year 03
30.06.2021Renewal fee patent year 04
06.06.2022Renewal fee patent year 05
29.06.2023Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
30.06.202407   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]US2009082265  (BARTEL PAUL [US], et al) [Y] 1-11 * paragraphs [0007] , [0386] , [0402] *;
 [Y]US2013164845  (POLACH KEVIN [US], et al) [Y] 1-11* paragraphs [0031] , [0165] , [0208] *;
 [Y]WO2015138628  (UNIV FLORIDA [US]) [Y] 1-11 * examples 1,5 *;
 [Y]WO2016179584  (UNIV SOUTH FLORIDA [US], et al) [Y] 1-11 * example 5 * * the whole document *;
 [Y]US2016376325  (MCFADDEN DOUGLAS GRANT [US], et al) [Y] 1-11 * paragraphs [0009] , [0049]; example 5 *;
 [Y]WO2017048466  (UNIV CALIFORNIA [US]) [Y] 1-11 * example 54 * * the whole document *;
 [Y]US2017088593  (ILDEFONSO CRISTHIAN J [US], et al) [Y] 1-11 * paragraphs [0041] , [0065] , [0078] *
International search[X]WO2016179584  (UNIV SOUTH FLORIDA [US], et al) [X] 1-20 * ; page 1, lines 9-11; page 5, lines 1-4; page 7, lines 1-12; page 13, lines 1-5; page 16, line 11; page 18, lines 9-13; page 24, lines 11-18; claims 1-10, 14-15 *;
 [A]  - TOMAIC, V et al., "Angelman syndrome-associated ubiquitin ligase UBE3A/E6 AP mutants interfere with the proteolytic activity of the proteasome", Cell Death and Disease, (20150129), vol. 6, pages 1 - 8, XP055495045 [A] 1-20

DOI:   http://dx.doi.org/10.1038/cddis.2014.572
 [A]  - DAILY, JL et al., "Adeno-Associated Virus-Mediated Rescue of the Cognitive Defects in a Mouse Model for Angelman Syndrome", PLOS ONE, (20111209), vol. 6, no. 12, page e27221, XP055556286 [A] 1-20

DOI:   http://dx.doi.org/10.1371/journal.pone.0027221
by applicantUS2013317018
 EP2724721
 WO2016179584
    - CLAYTON-SMITH, "Clinical research on Angelman syndrome in the United Kingdom: observations on 82 affected individuals", Am J Med Genet., (19930401), vol. 46, no. 1, pages 12 - 5
    - NICHOLLS, "New insights reveal complex mechanisms involved in genomic imprinting", Am J Hum Genet., (19940500), vol. 54, no. 5, pages 733 - 40
    - KISHINO et al., "UBE3A/E6-AP mutations cause Angelman syndrome", Nat Gen., (19970115), vol. 15, no. 1, pages 70 - 3
    - ALBRECHT et al., "Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons", Nat Genet., (19970900), vol. 17, no. 1, pages 75 - 8
    - TONAZZINI et al., "Impaired neurite contract guidance in ubuitin ligase E3a (Ube3a)-deficient hippocampal neurons on nanostructured substrates", Adv Healthc Mater., (20160400), vol. 5, no. 7, pages 850 - 62
    - KAPLAN et al., "Clinical heterogeneity associated with deletions in the long arm of chromosome 15: report of 3 new cases and their possible significance", Am J Med Genet., (19870900), vol. 28, no. 1, pages 45 - 53
    - BUITING et al., "Inherited microdeletions in the Angelman and Prader-Willi syndromes define an imprinting centre on human chromosome 15", Nat Genet., (19950400), vol. 9, no. 4, pages 395 - 400
    - GABRIEL et al., "A transgene insertion creating a heritable chromosome deletion mouse model of Prader-Willi and Angelman syndrome", Proc Natl Acad Sci U.S.A., (19990800), vol. 96, no. 16, pages 9258 - 63
    - KNOLL et al., "Angelman and Prader-Willi syndromes share a common chromosome 15 deletion but differ in parental origin of the deletion", Am J Med Genet., (19890000), vol. 32, no. 2, pages 285 - 90
    - MALCOLM et al., "Uniparental paternal disomy in Angelman's syndrome", Lancet., (19910323), vol. 337, no. 8743, pages 694 - 7
    - HUIBREGTSE et al., "A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or18", EMBO J., (19911200), vol. 10, no. 13, pages 4129 - 35
    - KUMAR et al., "Identification of HHR23A as a substrate for E6-associated protein-mediated ubiquitination", J Biol Chem., (19990625), vol. 274, no. 26, pages 18785 - 92
    - NUBER et al., "The ubiquitin-protein ligase E6-associated protein (E6-AP) serves as its own substrate", Eur J Biochem., (19980615), vol. 254, no. 3, pages 643 - 9
    - GREER et al., "The Angelman Syndrome protein Ube3A regulates synapse Development by ubiquitinating arc", Cell, (20100305), vol. 140, no. 5, doi:10.1016/j.cell.2010.01.026, pages 704 - 16, XP055057176

DOI:   http://dx.doi.org/10.1016/j.cell.2010.01.026
    - JIANG et al., "Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation", Neuron, (19981000), vol. 21, no. 4, doi:10.1016/S0896-6273(00)80596-6, pages 799 - 811, XP002122380

DOI:   http://dx.doi.org/10.1016/S0896-6273(00)80596-6
    - DAVIES et al., "Imprinted gene expression in the brain", Neurosci Biobehav Rev., (20050500), vol. 29, no. 3, doi:10.1016/j.neubiorev.2004.11.007, pages 421 - 430, XP004834425

DOI:   http://dx.doi.org/10.1016/j.neubiorev.2004.11.007
    - WEEBER et al., "Derangements of hippocampal calcium/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome", J Neurosci., (20030400), vol. 23, no. 7, doi:10.1523/JNEUROSCI.23-07-02634.2003, pages 2634 - 44, XP055734700

DOI:   http://dx.doi.org/10.1523/JNEUROSCI.23-07-02634.2003
    - BAYER et al., "Developmental expression of the CaM kinase II isoforms: ubiquitous γ- and δ-CaM kinase II are the early isoforms and most abundant in the developing nervous system", Brain Res Mol Brain Res., (19990618), vol. 70, no. 1, pages 147 - 54
    - MAHESHWARI et al., "Deficiency of Ube3a in Huntington's disease mice brain increases aggregate load and accelerates disease pathology", Hum Mol Genet., (20141201), vol. 23, no. 23, pages 6235 - 45
    - GARG S. et al., "The hybrid cytomegalovirus enhancer/chicken beta-actin promotor along with woodchuck hepatitis virus posttranscriptional regulatory element enhances the protective efficacy of DNA vaccines", J. Immunol., (20040701), vol. 173, no. 1, pages 550 - 558, XP002445286
    - HIGASHIMOTO, T. et al., The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors, (20070900), vol. 14, no. 17, pages 1298 - 304
    - COOPER, A.R. et al., "Rescue of splicing-mediated intron loss maximizes expression in lentiviral vectors containing the human ubiquitin C promoter", Nucleic Acids Res., (20150100), vol. 43, no. 1, doi:10.1093/nar/gku1312, pages 682 - 90, XP055343862

DOI:   http://dx.doi.org/10.1093/nar/gku1312
    - GUSTIN et al., "Tissue-specific variation of Ube3a protein expression in rodents and in a mouse model of Angelman syndrome", Neurobiol Dis., (20100900), vol. 39, no. 3, pages 283 - 91
    - HECK et al., "Analysis of cerebellar function in Ube3a-deficient mice reveals novel genotype-specific behaviors", Hum Mol Genet., (20080715), vol. 17, no. 14, pages 2181 - 9
    - LI et al., "Intra-ventricular infusion of rAAV-1-EGFP resulted in transduction in multiple regions of adult rat brain: a comparative study with rAAV2 and rAAV5 vectors", Brain Res., (20061129), vol. 1122, no. 1, pages 1 - 9
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.